[{"address1": "4-6 Bligh Street", "address2": "Suite 12.01, Level 12", "city": "Sydney", "state": "NSW", "zip": "2000", "country": "Australia", "phone": "61 2 9423 0881", "fax": "61 2 9423 0881", "website": "https://www.imugene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD", "age": 69, "title": "Executive Chairman", "yearBorn": 1956, "fiscalYear": 2025, "totalPay": 221438, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leslie  Chong", "title": "CEO, MD & Executive Director", "fiscalYear": 2025, "totalPay": 731390, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren Michael Keamy B.Com., CPA", "age": 52, "title": "CFO & Company Secretary", "yearBorn": 1973, "fiscalYear": 2025, "totalPay": 273848, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 7, "overallRisk": 10, "governanceEpochDate": 1767225600, "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.1913, "open": 0.26, "dayLow": 0.26, "dayHigh": 0.26, "regularMarketPreviousClose": 0.1913, "regularMarketOpen": 0.26, "regularMarketDayLow": 0.26, "regularMarketDayHigh": 0.26, "payoutRatio": 0.0, "beta": 2.718, "volume": 50000, "regularMarketVolume": 50000, "averageVolume": 12063, "averageVolume10days": 14498, "averageDailyVolume10Day": 14498, "bid": 0.1913, "ask": 0.2699, "bidSize": 15000, "askSize": 2500, "marketCap": 77303304, "fiftyTwoWeekLow": 0.0612, "fiftyTwoWeekHigh": 1.4416, "allTimeHigh": 15.946, "allTimeLow": 0.0612, "priceToSalesTrailing12Months": 17.581663, "fiftyDayAverage": 0.2218682, "twoHundredDayAverage": 0.3248889, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 57955936, "profitMargins": 0.0, "floatShares": 238211187, "sharesOutstanding": 322097133, "heldPercentInsiders": 0.15662, "heldPercentInstitutions": 0.03935, "impliedSharesOutstanding": 322097133, "bookValue": 0.1372885, "priceToBook": 1.7481436, "lastFiscalYearEnd": 1751241600, "nextFiscalYearEnd": 1782777600, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -69021616, "trailingEps": -0.21, "lastSplitFactor": "1:34", "lastSplitDate": 1751414400, "enterpriseToRevenue": 13.181, "enterpriseToEbitda": -0.86, "52WeekChange": -0.7565923, "SandP52WeekChange": 0.18594909, "quoteType": "EQUITY", "currentPrice": 0.24, "recommendationKey": "none", "totalCash": 21935432, "totalCashPerShare": 0.076, "ebitda": -67423168, "totalDebt": 10651476, "quickRatio": 1.443, "currentRatio": 1.885, "totalRevenue": 4396814, "debtToEquity": 23.653, "revenuePerShare": 0.02, "returnOnAssets": -0.3727, "returnOnEquity": -0.84540004, "grossProfits": 4396814, "freeCashflow": -62814992, "operatingCashflow": -75568512, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -6.44776, "financialCurrency": "AUD", "symbol": "IUGNF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "corporateActions": [], "regularMarketTime": 1767992400, "exchange": "PNK", "messageBoardId": "finmb_11113368", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1562333400000, "shortName": "Imugene, Ltd.", "longName": "Imugene Limited", "regularMarketChangePercent": 25.45739, "regularMarketPrice": 0.24, "marketState": "CLOSED", "regularMarketChange": 0.04869999, "regularMarketDayRange": "0.26 - 0.26", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 12063, "fiftyTwoWeekLowChange": 0.17879999, "fiftyTwoWeekLowChangePercent": 2.9215684, "fiftyTwoWeekRange": "0.0612 - 1.4416", "fiftyTwoWeekHighChange": -1.2016, "fiftyTwoWeekHighChangePercent": -0.8335183, "fiftyTwoWeekChangePercent": -75.659225, "earningsTimestampStart": 1753786740, "earningsTimestampEnd": 1754308800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.21, "fiftyDayAverageChange": 0.018131793, "fiftyDayAverageChangePercent": 0.08172326, "twoHundredDayAverageChange": -0.08488892, "twoHundredDayAverageChangePercent": -0.261286, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "displayName": "Imugene", "trailingPegRatio": null, "__fetch_time": "2026-01-10"}]